SOPHiA GENETICS SA (SOPH)
| Market Cap | 641.58M +116.4% |
| Revenue (ttm) | 90.97M +24.1% |
| Net Income | -81.13M |
| EPS | -1.09 |
| Shares Out | 85.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 556,830 |
| Open | 7.24 |
| Previous Close | 7.14 |
| Day's Range | 7.15 - 7.61 |
| 52-Week Range | 3.83 - 8.98 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 9.75 (+30.17%) |
| Earnings Date | Nov 3, 2026 |
About SOPH
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North Americ... [Read more]
Financial Performance
In 2025, SOPHiA GENETICS's revenue was $77.27 million, an increase of 18.56% compared to the previous year's $65.17 million. Losses were -$79.00 million, 26.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SOPH stock is "Strong Buy." The 12-month stock price target is $9.75, which is an increase of 30.17% from the latest price.
News
SOPHiA GENETICS Transcript: UBS Global Healthcare Conference
The global network and scalable analytics underpin clinical adoption and expanding biopharma work in CDx, real-world evidence, and AI predictors. Management sees biopharma as potentially reaching 50% of revenue and targets adjusted EBITDA profitability in Q4 2027.
SOPHiA GENETICS Earnings Call Transcript: Q3 2026
Q3 revenue rose 25% YoY, with record platform volume and strong U.S., liquid biopsy, and biopharma momentum; adjusted EBITDA loss improved 31%. FY26 revenue is now expected at the upper end of guidance, while FX and implementation timing remain factors.
SOPHiA GENETICS Slides: Q3 2026
SOPHiA GENETICS has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
SOPHiA GENETICS Earnings release: Q3 2026
SOPHiA GENETICS released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Sophia Genetics reports Q3 EPS (24c), consensus (20c)
Reports Q3 revenue $24.27M, consensus $24.03M. “Record analysis volume, strong performance in the U.S. market, and accelerating BioPharma momentum resulted in another excellent quarter as revenue grew...
Sophia Genetics backs FY26 revenue view $94M-$96M, consensus $95.23M
Backs FY26 adjusted EBITDA loss view $29M-$32M. The company said, “Full year revenue to be at the upper end of its previously issued guidance range of $94 million to $96…
SOPHiA GENETICS Reports Third Quarter 2026 Results
BOSTON and ROLLE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ende...
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026
BOSTON and ROLLE, Switzerland, Oct. 20, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for ...
Myriad, Sophia advance prostate cancer-specific genomic instability score tech
Myriad Genetics (MYGN) and Sophia Genetics (SOPH) announced a collaboration to advance new prostate cancer-specific genomic instability score technology to support precision oncology approaches with A...
Sophia Genetics and Myriad Genetics collaborate in prostate cancer score tech
Sophia Genetics (SOPH) and Myriad Genetics (MYGN) announced a collaboration to advance new prostate cancer-specific genomic instability score technology – or PrGIS – to support precision oncology appr...
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) t...
SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability...
Sophia Genetics price target raised to $9 from $8 at BTIG
BTIG analyst Mark Massaro raised the firm’s price target on Sophia Genetics (SOPH) to $9 from $8 and keeps a Buy rating on the shares. Sophia Genetics delivered a strong…
Sophia Genetics price target raised to $14 from $12 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Sophia Genetics (SOPH) to $14 from $12 and keeps a Buy rating on the shares post the Q2 report.
Sophia Genetics reports Q2 EPS (30c), one estimate (22c)
Reports Q2 revenue $23.3M, consensus $21.72M. Performance was driven by 60% volume growth in the U.S. and 80% revenue growth in Liquid Biopsy. We delivered an outstanding second quarter, growing…
Sophia Genetics raises FY26 revenue view to $94M-$96M from $92M-$94M
Consensus $93.38M. The company also expects an adjusted EBITDA loss between $29M and $32M.
SOPHiA GENETICS Earnings Call Transcript: Q2 2026
Q2 2026 saw 27% revenue growth and strong U.S. performance, with new CDx deals and a JV with MSK fueling future growth. Guidance was raised to $94M-$96M, and adjusted EBITDA loss improved 27% year-over-year. Cash reserves now stand at $107.7M.
SOPHiA GENETICS Earnings release: Q2 2026
SOPHiA GENETICS released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
SOPHiA GENETICS Slides: Q2 2026
SOPHiA GENETICS has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
SOPHiA GENETICS Reports Second Quarter 2026 Results
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter end...
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) s...
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
BOSTON and ROLLE, Switzerland, July 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced it will release its financial results for ...
Sophia Genetics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Sophia Genetics (SOPH) with a Buy rating and $12 price target Sophia integrates AI with multimodal genomic and clinical data to support oncology and rare-disease…
SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July...
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares
BOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced un...